Resumo:
En
|
Texto:
En
|
PDF:
En
ABSTRACT Objective: The aim of the study was to assess the impact of the Gamma coronavirus disease 2019 (COVID-19) variant on pregnant and postpartum women with Cardiovascular Disease (CVD). Methods: The Influenza Epidemiological Surveillance System database (SIVEP-Gripe), a compulsory notification system for cases of Severe Acute Respiratory Syndrome (SARS), was investigated for notified cases of pregnant and postpartum women with reported CVD and SARS due to COVID-19 between February 16, 2020 and May 1, 2021 (when vaccination began), was investigated. In this retrospective cohort, two groups were formed based on symptom onset date, according to the predominance of the variants: original (group 2020) and Gamma (group 2021). Cases with missing information on the presence or absence of CVD were excluded. The comparative analysis was controlled for confounding variables. Results: Among 703 COVID-19 cases notified with CVD (406 patients in 2020 and 297 patients in 2021), compared to 2020, cases in 2021 had more respiratory symptoms (90.6 % vs. 80.1 %, p < 0.001), greater ventilatory support need (75.3 % vs. 53.9 %, p < 0.001), more ICU admission (46.6 % vs. 34.3 %, p = 0.002), longer duration (20.59 ± 14.47 vs. 16.52 ± 12.98 days, p < 0.001), higher mortality (25.6 % vs. 15.5 %, p < 0.001), with more than two-times mortality likelihood in the third trimester (adjusted OR = 2.41, 95 % CI 1.50–3.88, p < 0.001) or puerperium periods (adjusted_OR = 2.15, 95 % CI 1.34-3.44, p = 0.001). Conclusions: In Brazil, pregnant and postpartum women with CVDs in the Gamma variant phase have higher morbidity and mortality than those affected by the original variant of Coronavirus-19. Objective 201 COVID19 COVID 19 (COVID-19 CVD. . (CVD) Methods SIVEPGripe, SIVEPGripe SIVEP Gripe , (SIVEP-Gripe) SARS, (SARS) COVID-1 16 202 1 when began, began began) cohort date variants group 2021. 2021) excluded variables Results 70 406 (40 29 2021, 90.6 906 90 6 (90. vs 801 80 80. 0.001, 0001 0.001 0 001 75.3 753 75 3 (75. 539 53 9 53. 46.6 466 46 (46. 343 34 34. 0.002, 0002 0.002 002 0.002) 20.59 2059 20 59 (20.5 1447 14 47 14.4 1652 52 16.5 1298 12 98 12.9 days 25.6 256 25 (25. 155 15 5 15. twotimes times adjusted 241 2 41 2.41 150388 50 88 1.50–3.88 adjusted_OR adjustedOR 215 2.15 1.343.44, 134344 1.34 3.44, 44 1.34-3.44 0.001. Conclusions Brazil Coronavirus19. Coronavirus19 Coronavirus 19. Coronavirus-19 COVID1 (COVID-1 (CVD (SIVEP-Gripe (SARS COVID- 7 40 (4 90. (90 8 000 0.00 00 75. (75 46. 4 (46 20.5 205 (20. 144 14. 165 16. 129 12. 25. (25 24 2.4 15038 1.50–3.8 21 2.1 1.343.44 13434 134 1.3 344 3.44 1.34-3.4 Coronavirus1 Coronavirus-1 (COVID- ( (9 0.0 (7 20. (20 (2 2. 1503 1.50–3. 1.343.4 1343 13 1. 3.4 1.34-3. Coronavirus- (COVID 0. 150 1.50–3 1.343. 3. 1.34-3 1.50– 1.343 1.34- 1.50 1.5